MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Improving Interobserver Variation in Reporting Gadolinium-Enhancing MRI Lesions in Multiple Sclerosis
Neurol 49:1682-1688, Barkhof,F.,et al, 1997